(Q34208736)

31 July 2017

Evaluating preclinical efficacy (English)

1 reference

31 July 2017

Mark A Atkinson

1

1 reference

PubMed ID

21849661

31 July 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

Science Translational Medicine

31 July 2017

1 reference

31 July 2017

3

1 reference

31 July 2017

96

1 reference

31 July 2017

96cm22

1 reference

Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease

31 July 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

The NOD mouse model of type 1 diabetes: as good as it gets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Standardizing experiments with NOD mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Continuous glucose monitoring in normal mice and mice with prediabetes and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Opinion: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Genetics, pathogenesis and clinical interventions in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Humanized mice in translational biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002757

10.1126/SCITRANSLMED.3002757

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

21849661